AUC-ROC, area under receiver operating characteristic; BHB, ß-hydroxybutyric acid; Biomarkers; C, control group; CA, cholic acid; CPT-11, irinotecan; Complicating toxicity; DBIL, direct bilirubin; DCA, deoxycholic acid; Diarrhea; FDR, false discovery rate; GCA, glycocholic acid; Gastrointestinal toxicity; IBIL, indirect bilirubin; IT-TOF/MS, ion trap/time-offlight hybrid mass spectrometry; Individual differences; Irinotecan; Lys, lysine; MSTFA, N-methyl-N-trifluoroacetamide; Metabolomics; NS, non-sensitive group; NSgt, non-sensitive for gastrointestinal toxicity; NSmt, non-sensitive for myelosuppression toxicity; OPLS-DA, orthogonal partial least-squares-discriminant analysis; PCA, principal component analysis; PLS-DA, partial least-squares-discriminant analysis; Phe, phenylalanine; Prediction; QC, quality control; RSD, relative standard deviation; S, sensitive group; Sgt, sensitive for gastrointestinal toxicity; Smt, sensitive for myelosuppression toxicity; T, CPT-11 treated group; Trp, tryptophan; UFLC, ultrafast liquid chromatography; VIP, variable importance in the projection; pFDR, false-discovery-rate-adjusted P value